Paul Reider
Corporate Officer/Principal chez COHERUS BIOSCIENCES, INC.
Fortune : 194 252 $ au 31/03/2024
Profil
Paul Reider is a member of the Clinical Advisory Board at Tetraphase Pharmaceuticals, Inc. He is also the Chief Commercial Officer at Coherus BioSciences, Inc. starting in 2022.
Previously, he worked as the Vice President of Sales & Strategic Accounts at Puma Biotechnology, Inc. from 2019 to 2021.
He also held a position as the General Manager at Ipsen Biopharmaceuticals Canada, Inc. Mr. Reider completed his undergraduate degree and MBA at Bowling Green State University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 09/04/2024 | 81 277 ( 0,07% ) | 194 252 $ | 31/03/2024 |
Postes actifs de Paul Reider
| Sociétés | Poste | Début |
|---|---|---|
| COHERUS BIOSCIENCES, INC. | Corporate Officer/Principal | 01/01/2021 |
| TETRAPHASE PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Anciens postes connus de Paul Reider
| Sociétés | Poste | Fin |
|---|---|---|
| PUMA BIOTECHNOLOGY, INC. | Sales & Marketing | 01/01/2021 |
| Ipsen Biopharmaceuticals Canada, Inc. | Corporate Officer/Principal | - |
Formation de Paul Reider
| Bowling Green State University | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| PUMA BIOTECHNOLOGY, INC. | Health Technology |
| COHERUS BIOSCIENCES, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Tetraphase Pharmaceuticals, Inc.
 Tetraphase Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetraphase Pharmaceuticals, Inc. is engaged in the development and production of novel tetracyclines for serious and life-threatening bacterial infections. It also develops eravacycline, a synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Waltham, MA. | Health Technology |
| Ipsen Biopharmaceuticals Canada, Inc. |
